Current Modulation of Guanylate Cyclase Pathway Activity—Mechanism and Clinical Implications
Molecules, 2021 For years, guanylate cyclase seemed to be homogenic and tissue nonspecific enzyme; however, in the last few years, in light of preclinical and clinical trials, it became an interesting target for pharmacological intervention.
Grzegorz Grześk, Alicja Nowaczyk
doaj +2 more sources
Regulation of Soluble Guanylate Cyclase by Matricellular Thrombospondins: Implications for Blood Flow [PDF]
Frontiers in Physiology, 2014 Nitric oxide (NO) maintains cardiovascular health by activating soluble guanylate cyclase (sGC) to increase cellular cGMP levels. Cardiovascular disease is characterized by decreased NO-sGC-cGMP signaling.
Natasha M Rogers +4 more
doaj +2 more sources
Protective Effects of Riociguat Against Contrast-Induced Nephropathy: An Experimental and Machine Learning-Based Study in Rats. [PDF]
Kaohsiung J Med SciABSTRACT Contrast‐induced nephropathy (CIN) is an important cause of acute kidney injury following exposure to iodinated contrast media, and effective preventive strategies remain limited. This study investigated the renoprotective effects of riociguat, a soluble guanylate cyclase stimulator, in an experimental rat model of CIN and explored machine ...
Tascanov MB +10 more
europepmc +2 more sources
Effects of Soluble Guanylate Cyclase Stimulators and Activators on Anti-Aggregatory Signalling in Patients with Coronary Artery Spasm [PDF]
International Journal of Molecular Sciences, 2023 John D. Horowitz, Yuliy Y Chirkov
exaly +2 more sources
Safety and efficacy of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis. [PDF]
World J Cardiol, 2020 BACKGROUND: The utility of novel oral soluble guanylate cyclase (sGC) stimulators (vericiguat and riociguat), in patients with reduced or preserved ejection fraction heart failure (HFrEF/HFpEF) is currently unclear.
Ullah W +6 more
europepmc +3 more sources
Frontiers in Pharmacology, 2023 Soluble guanylate cyclase agonists and guanylate cyclase C agonists are two popular drugs for diseases of the cardiovascular system and digestive systems. The common denominator in these conditions is the potential therapeutic target of guanylate cyclase.
Qinan Yin +15 more
doaj +1 more source
Activation mechanism of human soluble guanylate cyclase by stimulators and activators
Nature Communications, 2021 Soluble guanylate cyclase (sGC) is a validated drug target for cardiovascular diseases. Here, the authors report structures of human sGC in complex with NO and sGC stimulators or activator, providing insight into the mechanism of sGC activation by ...
Rui Liu, Yunlu Kang, Lei Chen
doaj +1 more source
Effects of different pulmonary vasodilators on arterial saturation in a model of pulmonary hypertension. [PDF]
PLoS ONE, 2013 BACKGROUND: Approved therapies for pulmonary arterial hypertension can induce oxygen desaturation when administered to patients with secondary forms of pulmonary hypertension (PH), probably due to an increase in ventilation/perfusion mismatch.
Eva Maria Becker +7 more
doaj +1 more source
Hemodynamic effects of a soluble guanylate cyclase stimulator, Riociguat, and an activator, Cinaciguat, during NO-modulation in healthy pigs [PDF]
, 2020 Cardiovascular diseases are often characterized by dysfunctional endothelium. To compensate for the related lack of nitric oxide (NO), a class of soluble guanylate cyclase (sGC) stimulators and activators have been developed with the purpose of acting ...
How, Ole-Jakob +2 more
core +1 more source
Dynamics of 6-Minute Walk Distance as a Predictor of Efficiency Specific Pulmonary Vasodilators
Рациональная фармакотерапия в кардиологии, 2022 Pulmonary hypertension is a severe and often rapidly progressive disease with a fatal outcome. Approved specific therapy with five classes of drugs – prostanoids, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase ...
A. A. Shmalts
doaj +1 more source